GlobeNewswire Inc.··NaIpsen Unveils Early-Stage Immuno-Oncology Breakthroughs at AACR Congress
Ipsen presents preclinical data for two first-in-class cancer candidates targeting solid tumors and gastrointestinal cancers, advancing its immuno-oncology pipeline.
IPSEYantibody-drug conjugatesolid tumors